Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models
Poster presentation to highlight preclinical efficacy of ATNM-400 across therapy-resistant breast cancer subtypes ATNM-400 is a first-in-class…